Clarity Pharmaceuticals (ASX:CU6)
Another healthcare pick of Bell Potter’s is Clarity, which is making rapid progress in the field of diagnostic imaging.
The company has been posting solid interim data from its clinical trials, particularly its prostate cancer imaging trial, Clarify.
With “64Cu SAR-bisPSMA… able to detect cancerous lesions in lymph nodes at a far earlier stage than the standard of care,” there’s significant potential for Clarity to revolutionise prostate cancer detection.
Bell Potter sees a flood of data coming in 2025, including “final data from Secure, the therapy trial also in prostate cancer,” which should further bolster the case for the drug.
Buy (Speculative); price target $10.00 – versus current price of $4.97
(20min delay)